MobiHealth News July 15, 2021
Mallory Hackett

Once combined, the company will operate as HeartFlow Group and will trade on the New York Stock Exchange under the symbol HFLO.

Heartflow, a company that specializes in creating computerized heart models to treat coronary diseases, announced plans to go public through a $2.4 billion merger with Longview Acquisition Corp. II, a special purpose acquisition company (SPAC) sponsored by affiliates of Glenview Capital Management.

Once combined, the company will operate as HeartFlow Group and trade on the New York Stock Exchange under the symbol HFLO.

The deal is expected to bring in $400 million in cash to be used for company growth, product development and other general corporate purposes, according to the announcement.

“The HeartFlow team is dedicated to providing...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Investments, Medical Devices, Trends
FDA Finalizes Rule to Phase Out Enforcement Discretion of Laboratory-Developed Tests
Five takeaways from GE HealthCare's first quarter 2024 results
Revitalizing innovation within the medical technology sector
UK sets out position on regulating AI as a medical device
QuidelOrtho taps retired Abbott diagnostics leader for CEO

Share This Article